This launch follows a strategic licensing agreement between Intas Pharmaceuticals Limited and Shanghai Henlius Biotech
Intas Pharmaceuticals has launched HETRONIFLY (Serplulimab), the first PD-1 inhibitor globally approved for the treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC), in the Indian market. This marks another major milestone, following the successful Launch in Europe.
This launch follows a strategic licensing agreement between Intas Pharmaceuticals Limited and Shanghai Henlius Biotech, further strengthening Intas’ oncology portfolio and reinforcing its commitment to delivering cutting-edge therapies to patients in India.
HETRONIFLY, introduced at approximately 75 per cent lower cost than the currently available immunotherapies for this indication, underscores Intas’ commitment to providing high-quality innovative therapies at affordable prices to cancer patients in India.
Binish Chudgar, Chairman and Managing Director, Intas Pharmaceuticals said, “The launch of HETRONIFLY reinforces our strategic position in oncology and reflects Intas’ commitment to accelerating access to globally validated therapies. It aligns with our operating model of delivering high-impact innovations to the Indian market with speed and cost-efficiency.”
